Skip to main content
Premium Trial:

Request an Annual Quote

Biognosys, FGCZ Collaborating on PRM-MS Software Development

Premium

Targeted proteomics firm Biognosys said this week that it is collaborating with the Functional Genomics Center Zurich on large-scale testing of its SpectroDive software for parallel-reaction monitoring mass spectrometry.

Under the collaboration, the parties will test the software on a range of different experiments and instrument set-ups in order to further develop the PRM method, Biognosys said.

Parellel-reaction monitoring uses high-resolution mass spec for quantification, relying on the upfront quadrupole of a Q-TOF or Q-Orbitrap machine to isolate a target precursor ion, and then monitor not just a few, but all of the resulting product ions.

The larger number of product ions monitored via PRM can improve the specificity of the analysis, since more transitions will be available to confirm a peptide ID. It can also reduce the effects of co-isolating background peptides.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.